Form4insider filings, from the source

SEC Form 4 · accession 0001573202-17-000006

RespireRx Pharmaceuticals Inc. · RSPI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Richard David Purcell Jr.
Officer — SVP - Research and Development
Period of report
Jun 30, 2017
Accepted (ET)
Jul 6, 2017 · 11:13 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000849636

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Common Stock Options (to purchase shares of Common Stock)F1$2.00Jun 30, 2017A40,000A—Jun 30, 2022common stock40,00040,000D
Common Stock Options (to purchase shares of Common Stock)F2$3.90holding————Jan 17, 2022common stock40,00040,000D
Common Stock Options (to purchase shares of Common Stock)F3,F4$7.3775holding————Mar 31, 2021common stock61,53961,539D
Common Stock Options (to purchase shares of Common Stock)F3,F5$6.396holding————Aug 18, 2022common stock9,2319,231D
Common Stock Options (to purchase shares of Common Stock)F3,F6$8.125holding————Jun 30, 2022common stock6,1546,154D

Explanation of responses